B

BioInvent International AB
STO:BINV

Watchlist Manager
BioInvent International AB
STO:BINV
Watchlist
Price: 26.95 SEK -0.74%
Market Cap: 1.8B SEK

Net Margin
BioInvent International AB

-960.9%
Current
-538%
Average
-6.8%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-960.9%
=
Net Income
-429.4m
/
Revenue
44.7m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SE
BioInvent International AB
STO:BINV
1.8B SEK
-961%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
303.1B USD
8%
US
Amgen Inc
NASDAQ:AMGN
151.7B USD
12%
US
Gilead Sciences Inc
NASDAQ:GILD
130.7B USD
2%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.8B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
115.9B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.2B USD
31%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
31.1B EUR
38%

BioInvent International AB
Glance View

Market Cap
1.8B SEK
Industry
Biotechnology

BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

BINV Intrinsic Value
84.6 SEK
Undervaluation 68%
Intrinsic Value
Price
B
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-960.9%
=
Net Income
-429.4m
/
Revenue
44.7m
What is the Net Margin of BioInvent International AB?

Based on BioInvent International AB's most recent financial statements, the company has Net Margin of -960.9%.

Back to Top